ImaginAb has signed a new license agreement to supply its ImmunoPET radiotracer to Boehringer Ingelheim.
The agreement builds on a long-term collaboration between the two companies that started in 2017. ImaginAb will supply clinical doses of its zirconium-89 CD8 ImmunoPET technology to Boehringer Ingelheim for use in the clinical development of its novel oncology therapeutics throughout North America and Europe.
ImaginAb will receive license fees and payments for providing ongoing technical, clinical, and regulatory support to implement its CD8 ImmunoPET technology, which can be used to image CD8 T cells in cancer patients. No other terms were disclosed.
